Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CERCNASDAQ:CRBPNASDAQ:HROWNASDAQ:MNOVNASDAQ:PLXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCERCCerecor$4.84-3.0%$2.60$1.98▼$4.50$464.68M1.441.27 million shs52,821 shsCRBPCorbus Pharmaceuticals$7.75+8.2%$7.77$4.64▼$61.90$87.61M3.05343,294 shs270,693 shsHROWHarrow$30.57-0.6%$28.06$20.85▼$59.23$1.13B0.41495,014 shs296,637 shsMNOVMediciNova$1.27$1.40$1.12▼$2.55$62.29M0.436,049 shs10,529 shsPLXPPLx Pharma$0.00$0.02▼$0.04$603K3.7912.96 million shs3,000 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCERCCerecor+4.39%+4.18%+24.75%-27.15%-59.98%CRBPCorbus Pharmaceuticals+3.77%-10.05%-2.05%+37.69%-85.51%HROWHarrow+0.75%-2.96%+8.96%+18.12%+46.18%MNOVMediciNova-3.05%-6.62%-9.93%-9.93%-11.81%PLXPPLx Pharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCERCCerecorN/AN/AN/AN/AN/AN/AN/AN/ACRBPCorbus Pharmaceuticals3.9466 of 5 stars3.60.00.04.72.02.50.6HROWHarrow2.8715 of 5 stars3.52.00.00.03.02.50.6MNOVMediciNova1.9631 of 5 stars3.82.00.00.02.20.80.0PLXPPLx PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCERCCerecor 0.00N/AN/AN/ACRBPCorbus Pharmaceuticals 3.10Buy$50.88556.45% UpsideHROWHarrow 3.00Buy$61.40100.85% UpsideMNOVMediciNova 3.50Strong Buy$7.00451.18% UpsidePLXPPLx Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MNOV, CRBP, PLXP, CERC, and HROW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025MNOVMediciNovaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.006/12/2025HROWHarrowBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$62.006/10/2025HROWHarrowWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform5/12/2025HROWHarrowHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$57.00 ➝ $60.005/7/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/7/2025CRBPCorbus PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$65.00 ➝ $58.005/7/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $56.005/7/2025CRBPCorbus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $40.004/9/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCERCCerecor$6.70M69.36N/AN/A$0.22 per share22.00CRBPCorbus PharmaceuticalsN/AN/AN/AN/A$11.69 per shareN/AHROWHarrow$199.61M5.62$0.14 per share225.02$1.95 per share15.68MNOVMediciNova$1M62.29N/AN/A$1.07 per share1.19PLXPPLx Pharma$4.54M0.00N/AN/A$1.30 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCERCCerecor-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/ACRBPCorbus Pharmaceuticals-$40.21M-$4.22N/AN/AN/AN/A-36.87%-32.87%8/5/2025 (Estimated)HROWHarrow-$17.48M-$0.56N/A76.43N/A-10.19%-25.01%-4.27%8/6/2025 (Estimated)MNOVMediciNova-$11.04M-$0.23N/AN/AN/AN/A-20.77%-19.68%8/6/2025 (Estimated)PLXPPLx Pharma-$46.13M-$1.85N/AN/AN/A-606.91%-291.11%-119.43%N/ALatest MNOV, CRBP, PLXP, CERC, and HROW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MNOVMediciNova-$0.14-$0.06+$0.08-$0.06N/AN/A5/8/2025Q1 2025HROWHarrow$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million5/6/2025Q1 2025CRBPCorbus Pharmaceuticals-$1.26-$1.39-$0.13-$1.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCERCCerecorN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/APLXPPLx PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCERCCerecor0.792.192.18CRBPCorbus PharmaceuticalsN/A11.8211.82HROWHarrow2.010.910.85MNOVMediciNovaN/A17.6617.66PLXPPLx PharmaN/A4.794.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCERCCerecor62.84%CRBPCorbus Pharmaceuticals64.64%HROWHarrow72.76%MNOVMediciNova9.90%PLXPPLx Pharma21.19%Insider OwnershipCompanyInsider OwnershipCERCCerecor45.70%CRBPCorbus Pharmaceuticals3.60%HROWHarrow15.16%MNOVMediciNova13.60%PLXPPLx Pharma8.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCERCCerecor3196.01 millionN/ANot OptionableCRBPCorbus Pharmaceuticals4012.24 million11.80 millionOptionableHROWHarrow18236.69 million31.12 millionOptionableMNOVMediciNova1049.05 million42.38 millionOptionablePLXPPLx Pharma1629.14 million26.53 millionNot OptionableMNOV, CRBP, PLXP, CERC, and HROW HeadlinesRecent News About These CompaniesAnalysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX) and Protalix (PLX)February 3, 2025 | markets.businessinsider.comGRAVITY Co (NASDAQ:GRVY) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comPLXp/USD - Pullix US DollarAugust 24, 2024 | investing.comProtalix Biotherapeutics Inc (PLX)January 30, 2024 | investing.comVertex Pharmaceuticals Inc VRTXJanuary 22, 2024 | morningstar.comMVietnam National Petroleum Group (PLX)October 23, 2023 | investing.comPLx Pharma Inc (PLXPQ)August 21, 2023 | uk.investing.comPharmaceutical R&D: the road to positive returnsJuly 16, 2023 | nature.comNPLXPQ PLx Pharma Inc.April 21, 2023 | seekingalpha.comPLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE(R) and Substantially All of its AssetsApril 13, 2023 | marketwatch.comWhy PLx Pharma Shares Are Nosediving TodayApril 12, 2023 | msn.comWhy iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving PremarketApril 12, 2023 | msn.comWhy PLx Pharma Shares Are Down Over 40% TuesdayApril 11, 2023 | msn.comPLx Pharma Inc. Receives Nasdaq Delisting NoticeApril 11, 2023 | finance.yahoo.comShort Volatility Alert: Plx Pharma IncApril 11, 2023 | msn.comPLx Pharma's Return On Capital Employed InsightsDecember 22, 2022 | msn.comPLx Pharma (PLXP) Q3 2022 Earnings Call TranscriptNovember 11, 2022 | seekingalpha.comPLx Pharma down after Q3 revenue fell 94% Y/YNovember 11, 2022 | seekingalpha.comPLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business UpdateNovember 10, 2022 | finance.yahoo.comPLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue EstimatesNovember 10, 2022 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNOV, CRBP, PLXP, CERC, and HROW Company DescriptionsCerecor NASDAQ:CERCCerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.Corbus Pharmaceuticals NASDAQ:CRBP$7.75 +0.59 (+8.24%) Closing price 04:00 PM EasternExtended Trading$7.56 -0.19 (-2.45%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Harrow NASDAQ:HROW$30.57 -0.20 (-0.65%) Closing price 04:00 PM EasternExtended Trading$30.90 +0.33 (+1.08%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.MediciNova NASDAQ:MNOV$1.27 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.27 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.PLx Pharma NASDAQ:PLXPPLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
